We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Download Mobile App





SARS-CoV-2 RT-PCR Test Uses Three-in-One Media Pooling Strategy to Increase Testing Throughput

By LabMedica International staff writers
Posted on 02 May 2022
Print article
Image: ViroKey SARS-CoV-2 RT-PCR Test v2.0 can now be used for pooling (Photo courtesy of Pexels)
Image: ViroKey SARS-CoV-2 RT-PCR Test v2.0 can now be used for pooling (Photo courtesy of Pexels)

A SARS-CoV-2 RT-PCR test uses a three-in-one media pooling strategy in order to provide the additional capability to be used for pooling.

The ViroKey SARS-CoV-2 RT-PCR Test v2.0, developed by Vela Diagnostics (Singapore) for the detection of SARS-CoV-2, received its EUA in September 2020, has CE mark in the EU, and is also approved by Australian TGA and multiple regulatory authorities globally. The FDA EUA authorized indication for the test for the detection of SARS-CoV-2 makes it authorized for use in laboratories certified under CLIA to perform high complexity tests, for the qualitative detection of RNA from the SARS-CoV-2 in pooled samples containing aliquots of transport media from up to three individual human anterior nasal swab specimens from not only individuals who are symptomatic, but also those who are asymptomatic and are participation in serial testing programs.

With at least three workflows available, laboratories can leverage that flexibility, depending on the throughput of their laboratory. This pooling strategy can be done by combining sample media of up to three patients to be tested as one sample, thereby only using resources needed for a single test. In a population with low positivity rate, this method increases testing throughput, improves laboratory efficiency, and reduces overall cost of testing.

"At Vela Diagnostics, we aim to provide solutions that work in real situations. With the FDA encouraging the development of tests for pooled samples, we have added the ability to aid in the increase of testing throughput," said Sam Dajani, Chairman and CEO of Vela Diagnostics.

"Laboratories can now leverage this capability to cope with the sudden surges that we have all experienced in waves throughout this pandemic," said Scott Cassidy, Director of Business Development. "We believe this is an important capability in the COVID-19 pandemic, where incidences and levels of testing can fluctuate at any time."

Related Links:
Vela Diagnostics 

Gold Supplier
SARS-CoV-2 Multiplex Real-Time RT-PCR Assay
GSD NovaPrime Plus SARS-CoV-2
New
Automatic Hematology Analyzer
BF-7200Plus
New
Urine Analyzer
R-600S
New
Gold Supplier
Automatic Biochemistry Analyzer
Biossays C8

Print article

Channels

Clinical Chem.

view channel
Image: The analysis pipeline used to investigate associations between blood metabolites, later life brain imaging measures, and genetic risk for Alzheimer’s disease (Photo courtesy of University College London)

Lipid Measurements Show Potential as Alzheimer’s Disease Biomarkers

Brain changes accompanying ageing are varied and can include pathologies that lead to cognitive impairment, the commonest of which is Alzheimer’s disease (AD). Identifying blood-based signatures of brain... Read more

Molecular Diagnostics

view channel
Image: Researchers have identified 10 new genes linked with hearing loss (Photo courtesy of 123rf.com)

Newly Identified Genes May Help to Screen and Treat Individuals with Hearing Loss

A massive genome-wide association study (GWAS) identified 10 novel gene loci associated with hearing loss, which may aid in screening and treating the disorder. Hearing loss is one of the top contributors... Read more

Hematology

view channel
Image: The CS-2500 analyzer features pre-analytic sample checks and four detection methods simultaneously on a single platform – coagulation end-point, chromogenic kinetic analysis, turbidimetric immunoassay and automated platelet aggregation (Photo courtesy of Sysmex)

Microvascular/Endothelial Dysfunction Contributes to Post-COVID Syndrome Pathogenesis

Post-COVID syndrome (PCS) or Long-COVID is an increasingly recognized complication of acute SARS-CoV-2 infection, characterized by persistent fatigue, reduced exercise tolerance chest pain, shortness of... Read more

Industry

view channel
Image: Sales of lateral flow assays in clinical testing are expected to register a CAGR of 5% through 2032 (Photo courtesy of Pexels)

Global Lateral Flow Assays Market to Surpass USD 11.5 Billion by 2032 Due to Evolving Applications

The global lateral flow assays market was valued at USD 7.2 billion in 2021 and is projected to register a CAGR of 4.7% during 2022-2032 to surpass USD 11.7 billion by the end of 2032, driven by the growing... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.